- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Emageon extends backlog, strikes credit deal
Current contracts signed by PACS and IT developer Emageon have extended the company's backlog of orders to a figure in excess of $100 million. Emageon attributes much of its success to partnering with large integrated delivery networks (IDNs), including
Current contracts signed by PACS and IT developer Emageon have extended the company's backlog of orders to a figure in excess of $100 million. Emageon attributes much of its success to partnering with large integrated delivery networks (IDNs), including Kaiser Permanente, Sisters of Mercy, Sutter Health, Allina Hospitals and Clinics, and Aurora Health Care. To date, more than 70 acute care hospitals and imaging facilities have implemented Emageon products. The company, which expects to complete 30 additional hospital implementations this year, currently has a customer base of more than 250 sites. Supporting future growth is a new agreement with IBM that will allow Emageon customers to obtain IBM Global Financing, providing a single-source agreement for financing Emageon products and services.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
